Forecasts 2025 profit below expectations Signs $250 million deal for lupus drug funding Shares drop more than 6% in early trading Feb 12 (Reuters) - Biogen (BIIB.O), opens new tab on Wednesday ...
(Reuters) -Biogen forecast 2025 profit below last year's levels and Wall Street expectations on Wednesday, hurt by a strong dollar and fierce competition for its drugs to treat multiple sclerosis.
Biotech company Biogen (NASDAQ:BIIB) will be announcing earnings results tomorrow morning. Here’s what to look for. Biogen beat analysts’ revenue expectations by 1.2% last quarter, reporting ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback